.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Medtronic recently announced its plans to buy SPR Therapeutics for $650 million. This strategic move aims to expand non-opioid options for chronic pain management. Consequently, healthcare providers will gain earlier access to minimally invasive therapies. Furthermore, this acquisition enhances Medtronic's extensive neuromodulation portfolio.
Chronic pain affects millions of individuals globally and severely impacts their quality of life. Traditional interventions often rely on invasive surgeries or potentially addictive opioid prescriptions. However, clinical demand is rapidly shifting toward safer and less invasive alternatives. Therefore, the medical community actively seeks temporary solutions that bridge the gap in patient care. This transaction addresses that exact need by offering a non-permanent neurostimulation option.
The acquisition centers on SPR Therapeutics' FDA-cleared SPRINT Peripheral Nerve Stimulation (PNS) System. Specifically, this innovative device delivers a percutaneous, 60-day temporary treatment. Moreover, it does not require a permanent surgical implant. In addition, real-world clinical data involving over 6,100 patients demonstrated significant success. Specifically, more than 71% of patients reported remarkable pain relief and improved quality of life. Consequently, clinicians can deploy this system much earlier in the patient’s treatment plan.
Medtronic plans to complete this cash transaction in the first half of its fiscal year 2027. Currently, the deal is subject to standard regulatory approvals and customary closing conditions. Until the deal officially closes, both companies will continue to operate as separate entities. Additionally, this purchase represents Medtronic's third major medical technology acquisition this year. Ultimately, this strategic expansion highlights Medtronic's strong commitment to advancing patient-centered neuromodulation technologies.
Q1: What is the SPRINT PNS System?
The SPRINT PNS System is an FDA-cleared, temporary peripheral nerve stimulation device. Specifically, it delivers a short-term, 60-day therapy to provide significant pain relief without requiring a permanent surgical implant.
Q2: Why did Medtronic decide to acquire SPR Therapeutics?
Medtronic acquired the company to expand its chronic pain management portfolio. Consequently, this acquisition allows Medtronic to offer earlier, less invasive, and non-opioid pain relief options to patients.
Q3: When is the acquisition of SPR Therapeutics expected to close?
The transaction is expected to close in the first half of Medtronic's fiscal year 2027. However, this timeline is subject to customary regulatory approvals.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Medtronic has announced its plans to acquire SPR Therapeutics for $650 million, expanding its non-opioid, minimally invasive chronic pain treatments....
2 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
